NEW YORK, July 31, 2017 -- According to a new research report “Age-related macular degeneration Therapeutic Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Age-related macular degeneration Therapeutic pipeline currently exhibits a pipeline with 55 drug candidates.
Browse Detailed Report Description at: https://www.psmarketresearch.com/market-analysis/age-related-macular-degeneration-therapeutics-pipeline-analysis
The Age-related Macular Degeneration pipeline analysis report covers approximately 55 drug candidates in the pipeline in different stages of development.
As per the findings of the research, most of the drug candidates of Age-related macular degeneration pipeline are being developed to be administered by intra-vitreal route.
Many technologies are being developed that can bring the innovative treatment which can control the progression of Age-related macular degeneration. Some of these technologies include but are not limited to, HINGESCREEN technology platform, and CrossMab technology platform.
There are different novel molecule types that are present in the therapeutic pipeline of Age-related macular degeneration. Opregen is being developed by Cell Cure Neurosciences. Opregen is a stem cells molecule type useful in the treatment of Age-related macular degeneration.
Some of the key players developing drugs for Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche, and others.
Make Enquiry Before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=age-related-macular-degeneration-market
Related Research
Phosphatidylinositol 3-Kinase (PI3K) Inhibitors Pipeline Analysis, 2017
Factors such as emerging combination therapies and biomarker identification are driving the growth of the PI3K inhibitors pipeline. Combination therapies are being used to stop further cancer growth and kill the cancerous cells. Also, combining novel drugs against different signaling pathways as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.
Venous Thromboembolism Therapeutics Pipeline Analysis, 2017
According to American Heart Association, Venous thromboembolism (VTE) collectively develops as a combination of deep vein thrombosis (DVT) and pulmonary embolism (PE), two life-threatening conditions. Venous thromboembolism is a common and preventable disease in which the clot formation occurs in the vein associated with Venous thromboembolism. In deep vein thrombosis, a clot formed in a deep vein, usually in the leg. Pulmonary embolism is a deep vein thrombosis clot that breaks free from a vein wall, travels to the lungs and blocks some or all of the blood supply. Blood clots in the thigh are more likely to break off and travel to the lungs than the clots in lower leg or other parts of the body.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook


Italy Fines Apple €98.6 Million Over App Store Dominance
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 



